| Mar'20 | Mar'19 | |||||
|---|---|---|---|---|---|---|
Operating activities: | ||||||
Net loss | ||||||
0 | 0 | |||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Stock-based compensation | ||||||
0 | 0 | |||||
Share in net loss of equity method investments | ||||||
- | 0 | |||||
Accretion of 2027 Notes and term loans | ||||||
0 | 0 | |||||
Acquired in-process research and development assets | ||||||
- | 0 | |||||
LEO call option expense (income) | ||||||
0 | 0 | |||||
Other noncash adjustments | ||||||
0 | 0 | |||||
Changes in operating assets and liabilities: | ||||||
Prepaid expenses and other current assets | ||||||
0 | 0 | |||||
Other assets | ||||||
0 | 0 | |||||
Accounts payable | ||||||
0 | 0 | |||||
Accrued compensation and benefits | ||||||
0 | 0 | |||||
Accrued research and development liabilities | ||||||
0 | 0 | |||||
Accrued professional services | ||||||
0 | 0 | |||||
Operating lease liabilities | ||||||
0 | - | |||||
Other accrued and other liabilities | ||||||
0 | 0 | |||||
Net cash used in operating activities | ||||||
0 | 0 | |||||
Investing activities | ||||||
Maturities of marketable securities | ||||||
0 | - | |||||
Cash paid for in-process research and development assets acquired | ||||||
- | 0 | |||||
Purchases of property and equipment | ||||||
0 | 0 | |||||
Net cash provided by (used in) investing activities | ||||||
0 | 0 | |||||
Financing activities | ||||||
Proceeds from issuance of 2027 Notes | ||||||
0 | - | |||||
Issuance costs and discounts associated with issuance of 2027 Notes | ||||||
0 | - | |||||
Purchase of capped calls | ||||||
0 | - | |||||
Repurchase of common stock | ||||||
0 | - | |||||
Proceeds from repayment of nonrecourse notes | ||||||
- | 0 | |||||
Proceeds from at-the-market issuance of noncontrolling interest by Eidos, net | ||||||
0 | - | |||||
Proceeds from issuance of redeemable convertible noncontrolling interests to third-party investors | ||||||
0 | - | |||||
MyoKardia distributions | ||||||
- | 0 | |||||
Payment of deferred offering costs | ||||||
- | 0 | |||||
Proceeds from stock option exercises, net of repurchases | ||||||
0 | 0 | |||||
Net cash provided by (used in) financing activities | ||||||
0 | 0 | |||||
Net increase (decrease) in cash, cash equivalents and restricted cash | ||||||
0 | 0 | |||||
Supplemental Disclosures of Cash Flow Information: | ||||||
Cash paid for interest | ||||||
0 | 0 | |||||
Supplemental Disclosures of Non-Cash Investing and Financing Information: | ||||||
Issuance costs associated with issuance of 2027 Notes included in other accrued and other liabilities | ||||||
0 | - | |||||
Recognition of property and equipment previously classified in other assets | ||||||
0 | - | |||||
Operating lease right-of-use assets obtained in exchange for operating lease obligations | ||||||
0 | - | |||||
Transfers from (to) noncontrolling interest (Note 6) | ||||||
0 | 0 | |||||